



Canadian Society for Chemistry | *For Our Future*
Société canadienne de chimie | *Pour notre avenir*

The Canadian Society for Chemistry (CSC) VP Election CSC AGM May 28, 2020

Prepared by: CSC Nominations Committee, chaired by Kim Baines, Past-President CSC.

Date: May 26, 2020

The following candidates have agreed to stand as a director for a term of three (3) years if elected and have agreed to hold the following offices during that term:

Vice-President	2020–2021
President	2021–2022
Past President	2022–2023

Zhongxin Zhou, FCIC, Gilead Alberta

Dr. Zhongxin Zhou, FCIC, is currently Executive Director and the Head of Process Development and Manufacturing at Gilead Alberta, overseeing the activities of organic process development, technical operations and laboratory and plant manufacturing for active pharmaceutical ingredients and advanced intermediates. After he received his BSc (Hons) and MSc, Dr. Zhou had worked at Hubei Research Institute of Chemistry in China for five years, focusing on organic process research and development for the synthesis of commercially important fine chemicals. He then obtained his PhD in 1994 from the Memorial University of Newfoundland, with Dr. Chet Jablonski. After close to two-year stay as postdoctoral fellow, with Dr. Howard Alper, at the University of Ottawa, he joined Raylo Chemicals, which later became Gilead Alberta. During this period, he pursued and received his MBA from the University of Alberta.

Dr. Zhou expanded his role from process chemist to management of process research and development, as well as manufacturing operations. Throughout the 24 years working in the pharmaceutical industry, in collaboration with people from different organizations, he has led and directed the development efforts of more than 200 drug substances, each of which involved in multiple steps (between 5 to 45 steps) of transformations with full range of advanced chemical reactions. The research and development efforts in his team include route scouting, process parameter screening and optimization, process control strategy development. These have resulted in the implementation of numerous commercially viable processes for the manufacture of multi-kilograms to hundreds of metric tons of drug substances for clinical development and commercial supplies. In addition, the process knowledge generated during the process research and development have been part of the critical documents for a great number of regulatory filings that are essential parts of the commercialization of medical products. The work from his team have contributed to the commercial launches of more than 20 novel drug substances all over the world that are used in many drug products for the treatment of diseases in various therapeutic areas, including HIV, HCV, oncology and inflammation, that have saved lives of millions of people in the world.

William Scott Hopkins, MCIC, University of Waterloo

Scott Hopkins is an Associate Professor of chemistry at the University of Waterloo. He completed his PhD in high-resolution spectroscopy in 2006 at the University of New Brunswick, then undertook postdoctoral studies in photodissociation dynamics and gas phase cluster science at Queen's University in Kingston, the University of Cambridge, and the University of Oxford where he held the Ramsay Memorial Fellowship. Scott joined the University of Waterloo in 2011 where he established a research program that focuses on determining the structures and properties of gas phase clusters. To date he has published 68 peer-reviewed articles and has coauthored three patents. For his work, he was awarded a University Research Chair at Waterloo and an Early Researcher Award from the Province of Ontario. He is currently serving on the NSERC Evaluation Group for Chemistry for Discovery Grants.